Gosselies, Belgium

Time filter

Source Type

A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.


An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.


Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 3.81M | Year: 2013

BIO-INSPIRE will develop a new horizon in Orthopaedic Therapy by: 1. Development of a technology platform that consists of new bio-active and bio-mimetic materials and their therapeutic applications for bone regenerative purposes. 2. Training of the next generation of leading Tissue Engineering scientists in a multi-disciplinary way, leading them towards excellence in individual disciplines in combination with a multidisciplinary, holistic view on the (bone tissue) biological systems to be studied. The consortium consists of a unique alliance of carefull selected Partners with a high reputation in a set of complementary disciplines (as required for a multi-disciplinary program in the field of bone regeneration) consisting of Fraunhofer, Medicyte (field of Cell therapy), Fujifilm Life Science (Bio-Materials), ISTEC (Bone Mineralisation), Erasmus MC (Growth Factors), Un of Bologna, Bone Therapeutics (Orthopaedic Therapy). This combination provides a unique multidisciplinary research environment for 16 hosted Fellows. The industrial participation is high, being the coordinator and chairing the project and hosting 8 Fellows out of 16 Fellows, immersing those Fellows in both an academic and an industrial research setting. This project will provide: - A new generation of scientists, capable to participate in multi-disciplinary, pan-European project teams, mastering their individual disciplines in combination with a multi-disciplinary, holistic view. - A new class of bio-material prototypes, bio-mimetic, triggering cascades of bone regenerative processes, ready for clinical trials beyond BIO-INSPIRE for a variety of therapeutic needs. - A robust pan-European network for development of bio-mimetic materials, consisting of Academic and Industrial participants, acting as an European Network for Innovation and Education for talented scientists in the field of tissue regenerative technologies and medical therapies.


Patent
Bone Therapeutics and Enrico Bastianelli S.P.R.L. | Date: 2013-09-26

The invention concerns pharmaceutical formulations comprising solvent/detergent (S/D)-treated plasma and a glycosaminoglycan such as hyaluronic acid, and their use for treating diseases, particularly musculoskeletal diseases.


The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression.


The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.


An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.


Patent
Bone Therapeutics | Date: 2013-03-12

The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.


Patent
Free University of Colombia, University of Liège and Bone Therapeutics | Date: 2012-06-11

The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, and an agonist of IL-8 receptor, for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but not limited to non-union fractures, mal-union fractures, or delayed union fractures.


Patent
Free University of Colombia, University of Liège and Bone Therapeutics | Date: 2012-06-11

The present application discloses particularly interleukin-8 (IL-8) as a novel biomarker for the prediction, diagnosis, prognosis and/or monitoring of impaired bone fracture healing; and related methods, uses and kits.

Loading Bone Therapeutics collaborators
Loading Bone Therapeutics collaborators